STAT+: Pharmalittle: U.S. officials and Pfizer to meet over Covid-19 booster shots; FDA full approval for vaccines may not be a game changer
Good morning, everyone, and nice to see you again after we took an extended break….
Category: STAT+
STAT+: A Johns Hopkins startup aims to shake up AI in medicine with research-first approach
The formula for launching a machine learning company in health care looks something like this:…
STAT+: Pharmalittle: Even FDA officials balked at the broad Aduhelm label; CDC and FDA are dubious about Covid booster shots
Good morning, one and all. Damian Garde here, filling in for Ed Silverman in the…
STAT+: In a sweeping executive order, Biden endorses importing drugs from Canada and orders a bigger drug pricing plan by late August
WASHINGTON — President Biden on Friday will take aim at the pharmaceutical industry by ordering…
STAT+: FDA extends shelf life for glaucoma drug discontinued by Pfizer, but patients remain concerned
In a bid to calm anxious patients, the Food and Drug Administration has extended the…
STAT+: House Democrats say pharma stock buybacks and dividends exceed R&D spending
A Congressional committee released a report on Thursday showing the 14 largest drug makers spent…
STAT+: FDA’s expansive Alzheimer’s drug approval surprised even top agency officials
WASHINGTON — The Food and Drug Administration’s contentious decision to approve a new Alzheimer’s drug…
STAT+: Former Genentech scientist convicted of stealing trade secrets given to former JHL Biotech execs
A former Genentech principal scientist and her husband were convicted of stealing trade secrets and…
STAT+: Purdue reaches deal with 15 states in a significant step toward bankruptcy plan approval
Fifteen states have agreed to drop their long-standing objections to a contentious bankruptcy plan to…
STAT+: Pharmalittle: In rare move, FDA revises label for Biogen Alzheimer’s drug; former compounding exec gets added jail time
Good morning, everyone, and how are you today? The sun is trying to peek through…
STAT+: FDA, under fire from critics, revises prescribing information for Biogen’s Alzheimer’s drug
The Food and Drug Administration on Thursday changed the prescribing label for Biogen’s Alzheimer’s treatment…
STAT+: Sonde’s voice health tracking comes to Qualcomm’s smartphone chips
Vocal biomarker startup Sonde has been quietly plotting a way to make tracking respiratory and…
STAT+: Pharmalittle: Another lawmaker calls for probe of FDA approval of Alzheimer’s drug; Roche urged to lower price of Covid-19 therapy
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
How Doximity parlayed its popularity with doctors into a blockbuster IPO
Doximity exploded onto the public markets last month with an IPO that saw share values…
STAT+: Doctors Without Borders urges Roche to cut price of drug now recommended for Covid-19
After the World Health Organization recommended a Roche (RHHBY) drug to treat severe Covid-19, Doctors…
STAT+: The failure of a cancer drug study leaves Cel-Sci on the brink of collapse
The failure of Cel-Sci’s immunotherapy treatment called Multikine to prolong the survival of patients with…
.jpg)
STAT+: Pharmalittle: Purdue wants to shower employees with $34.7 million in bonuses; Emergent faces shareholder suits
Good morning, everyone, and welcome to another working week, albeit an abbreviated one on this…
STAT+: If Apple takes aim at fall-prevention, will the rest of the health system hear it?
Using troves of data from iPhone users, Apple thinks it’s cracked an elusive problem: Identifying…
STAT+: The most intriguing health tech deals of the year (so far)
In the world of digital health, money is flying around like never before. All that…
STAT+: Is the Alzheimer’s Association really pushing Biogen to lower its new drug’s price — or is it lip service?
WASHINGTON — The Alzheimer’s Association stunned Washington last month when it urged Biogen to lower…
STAT+: Supreme Court to take up hospitals’ challenge to Medicare drug pay cuts
WASHINGTON — In a win for safety-net hospitals, the Supreme Court decided to hear their…
STAT+: Pharmalittle: Glaxo rejects hedge fund’s demands; FTC approves resolutions to probe pharma repeat offenders
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Inside the ‘land grab’ for virtual-first care: how an unprecedented flurry of deals is shaping the new digital health landscape
Teladoc’s blockbuster merger with Livongo in 2020 would’ve been unthinkable just a few years ago….
STAT+: Nestle Health Science will split profits from Seres microbiome drug, if it’s approved
Seres Therapeutics has announced a new deal with its long-time partner, Nestle Health Science, to…
STAT+: Pharmalittle: Glaxo under more pressure from activist investor; WHO urges Gilead to lower price of black-fungus drug
Hello, everyone, and how are you today? A shiny sun and delightful breeze are enveloping…
STAT+: In a new role at health tech startup Maven, Neel Shah wants to make sure pregnant people aren’t ‘lost’
When celebrated Boston OB-GYN Neel Shah first learned of the chance to help build a…
STAT+: The biotech scorecard for the third quarter: 12 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT+: Washington’s antitrust push could limit Amazon, Google’s health care ambitions
WASHINGTON — Washington is abuzz with an ambitious new antitrust effort to rein in the…
STAT+: Gene therapy to regenerate cardiac muscle after a heart attack passes a key test in pigs
By delivering a viral payload of gene silencers directly to the heart, scientists have developed…
STAT+: Pharmalittle: Most doctors disagree with FDA approval of the Alzheimer’s drug; women underrepresented in life sciences C-suites
Good morning, everyone, and how are you today? The heat continues to rise here on…
STAT+: Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug
A majority of U.S. physicians disagree with the decision by the Food and Drug Administration…
STAT+: The health tech tracker for the third quarter: 11 pivotal industry events to watch
The third quarter will answer crucial questions about the near-term future of digital health. Will…
STAT+: Pharmalittle: How Biogen and FDA formed a back channel to push an Alzheimer’s drug; Sanofi to dive into mRNA vaccine development
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: ‘This is not enough’: Walmart’s plan to sell another private label insulin is met with skepticism
Amid a national outcry over the cost of insulin, Walmart (WMT) plans to sell a…
STAT+: Inside ‘Project Onyx’: How Biogen used an FDA back channel to win approval of its polarizing Alzheimer’s drug
It was perhaps the most contentious drug approval in decades, shocking drug company executives, insurance…
STAT+: Will Gilead’s early data for its CAR-T therapy give it an edge over Bristol Myers?
Gilead Sciences (GILD) released top-line trial data for its Yescarta treatment that may allow the…
STAT+: Pharmalittle: Biogen Alzheimer’s drug will cost Medicare how much? Intellia data suggest a first for genome editing
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Experts debate the value of digital coaching for type 2 diabetes
Even before the pandemic drove an extreme shift toward telemedicine, diabetes care was leading the…
.jpg)
STAT+: In an about-face, Health Canada allows a controversial rare disease drug back on the market
In yet another twist in a complicated tale, Health Canada has reinstated approval of a…
STAT+: In a first for genome editing, Intellia Therapeutics reports positive early data on in vivo CRISPR therapy
In a major milestone for the still-young field of genome editing, Intellia Therapeutics said Saturday that…
STAT+: Pharma has a ‘hidden’ influence over U.K. Parliament members through funding, analysis shows
The pharmaceutical industry has developed a “hidden web of policy influence” over members of the…
STAT+: As Covid-19 rages in India, Gilead faces pressure to lower price of drug to treat rare infection
Over the past few months, thousands of people in India who survived Covid-19 returned to…
STAT+: Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s drugs?
In an unexpected move, U.S regulators granted Eli Lilly (LLY) a breakthrough designation for its…
STAT+: Pfizer halts global distribution of smoking cessation pill as it tests for potential carcinogens
After finding potential carcinogens in some lots of Chantix, Pfizer (PFE) late last month halted…
STAT+: Pharmalittle: Lilly seeks speedy U.S. approval for its Alzheimer’s drug; FDA’s Woodcock ‘not concerned’ about criticism
Hello, everyone, and nice to see you again after a day off. We can explain…
STAT+: In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment
Eli Lilly said Thursday that it will seek a fast U.S. approval for its drug…
STAT+: 5 companies harnessing AI for drug discovery to watch
A decade ago, the business of drug discovery changed forever. Machine learning researchers were beginning…
STAT+: FDA’s Woodcock is just ‘not that concerned’ about the criticism over Biogen’s Alzheimer’s drug, Aduhelm
WASHINGTON — The Food and Drug Administration has been without a permanent commissioner for six…
STAT+: Arcus’ anti-TIGIT immunotherapy shows ‘encouraging’ tumor response, but likely leaves investors wanting more
Arcus Biosciences said Wednesday that a two-drug combination that includes an anti-TIGIT antibody delivered “encouraging…
STAT+: What the cancer research community can learn from the Covid-19 response
The Covid-19 pandemic’s rapid spread across the world demanded a quick, collaborative response. Now, experts…